FI2892330T3 - Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi - Google Patents

Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi Download PDF

Info

Publication number
FI2892330T3
FI2892330T3 FIEP13834735.6T FI13834735T FI2892330T3 FI 2892330 T3 FI2892330 T3 FI 2892330T3 FI 13834735 T FI13834735 T FI 13834735T FI 2892330 T3 FI2892330 T3 FI 2892330T3
Authority
FI
Finland
Prior art keywords
human
mouse
csf
nucleic acid
acid encoding
Prior art date
Application number
FIEP13834735.6T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Richard Flavell
Markus Manz
Anthony Rongvaux
Till Strowig
Tim Willinger
George Yancopoulos
Sean Stevens
Andrew Murphy
Original Assignee
Univ Yale
Institute For Res In Biomedicine Irb
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Institute For Res In Biomedicine Irb, Regeneron Pharma filed Critical Univ Yale
Application granted granted Critical
Publication of FI2892330T3 publication Critical patent/FI2892330T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FIEP13834735.6T 2012-09-07 2013-09-06 Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi FI2892330T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698002P 2012-09-07 2012-09-07
US201361775171P 2013-03-08 2013-03-08
PCT/US2013/058448 WO2014039782A2 (en) 2012-09-07 2013-09-06 Genetically modified non-human animals and methods of use thereof

Publications (1)

Publication Number Publication Date
FI2892330T3 true FI2892330T3 (fi) 2023-03-25

Family

ID=50237767

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP13834735.6T FI2892330T3 (fi) 2012-09-07 2013-09-06 Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi

Country Status (18)

Country Link
US (6) US9820476B2 (enExample)
EP (3) EP2892330B1 (enExample)
JP (5) JP6283031B2 (enExample)
KR (7) KR102287541B1 (enExample)
CN (4) CN104955326B (enExample)
AU (3) AU2013312359B8 (enExample)
CA (1) CA2881468C (enExample)
DK (1) DK2892330T3 (enExample)
ES (2) ES2938342T3 (enExample)
FI (1) FI2892330T3 (enExample)
IL (4) IL282472B2 (enExample)
IN (1) IN2015DN02032A (enExample)
MX (2) MX364714B (enExample)
NZ (3) NZ741951A (enExample)
PT (1) PT2892330T (enExample)
RU (2) RU2768282C2 (enExample)
SG (2) SG10201701759VA (enExample)
WO (1) WO2014039782A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3040377C (en) 2009-10-06 2025-12-30 Yale University Genetically modified mice and engraftment comprising the knock-in of a human thrombopoietin (tpo) gene
ES3040596T3 (en) * 2011-02-15 2025-11-03 Regeneron Pharma Humanized m-csf mice and uses thereof
KR102287541B1 (ko) * 2012-09-07 2021-08-10 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
EP4389764B1 (en) * 2012-11-05 2026-03-18 Regeneron Pharmaceuticals, Inc. Genetically modified rodents and methods of use thereof
DK3175706T3 (en) 2013-09-23 2019-03-04 Regeneron Pharma Non-human animals with a humanized signal regulatory protein gene
SMT201900177T1 (it) 2013-10-15 2019-05-10 Regeneron Pharma Animali con il-15 umanizzata
SG10201811701YA (en) 2013-11-19 2019-01-30 Regeneron Pharma Non-human animals having a humanized a proliferation-inducing ligand gene
JP6598798B2 (ja) 2014-05-05 2019-10-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｃ５およびｃ３動物
NO2785538T3 (enExample) 2014-05-07 2018-08-04
KR20250096864A (ko) 2014-05-19 2025-06-27 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
KR102617691B1 (ko) 2014-12-05 2023-12-27 리제너론 파마슈티칼스 인코포레이티드 인간화 분화 클러스터 47 유전자를 가진 비인간 동물
NZ731954A (en) 2014-12-09 2024-11-29 Regeneron Pharma Non-human animals having a humanized cluster of differentiation 274 gene
CN113699116A (zh) 2014-12-10 2021-11-26 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
JP6752221B2 (ja) 2015-04-13 2020-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｓｉｒｐａ−ｉｌ１５ノックインマウス及びその使用方法
AU2016358101B2 (en) 2015-11-20 2022-12-01 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized Lymphocyte-activation gene 3
CN108779159B (zh) 2016-02-04 2022-12-30 瑞泽恩制药公司 具有经改造的angptl8基因的非人动物
JP6980674B2 (ja) 2016-02-29 2021-12-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. ヒト化ｔｍｐｒｓｓ遺伝子を有する齧歯類
CN106119284A (zh) * 2016-06-27 2016-11-16 北京维通达生物技术有限公司 一种用于构建免疫缺陷动物模型的产品及其应用
EP3547831A1 (en) * 2016-11-30 2019-10-09 The Jackson Laboratory Humanized mouse model with improved human innate immune cell development
CN110868850B (zh) * 2017-05-12 2023-07-14 杰克逊实验室 缺乏i类和ii类mhc的nsg小鼠
HRP20240999T1 (hr) 2018-07-16 2024-10-25 Regeneron Pharmaceuticals, Inc. Glodavački modeli bolesti ditra i njihova upotreba
WO2020068615A1 (en) * 2018-09-24 2020-04-02 Albert Einstein College Of Medicine Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111073907B (zh) * 2018-12-25 2025-07-29 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf1基因改造非人动物的构建方法及应用
CN111118019B (zh) * 2018-12-25 2021-03-16 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il3基因改造非人动物的构建方法及应用
US20220354098A1 (en) * 2019-07-17 2022-11-10 Yale University Genetically Modified Non-Human Animals and Methods of Use Thereof
WO2021083366A1 (en) * 2019-11-01 2021-05-06 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with human or chimeric thpo
US11339279B2 (en) * 2020-04-01 2022-05-24 Chevron Phillips Chemical Company Lp Dual catalyst system for producing LLDPE and MDPE copolymers with long chain branching for film applications
CN114853871B (zh) * 2021-04-20 2024-04-05 百奥赛图(北京)医药科技股份有限公司 Csf1和/或csf1r基因人源化的非人动物及其构建方法和应用
WO2024020057A1 (en) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
CN121335619A (zh) 2023-06-16 2026-01-13 瑞泽恩制药公司 载体、经基因修饰的细胞和包含其的经基因修饰的非人动物
WO2025171307A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
WO1988003173A2 (en) 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
ES2071620T3 (es) 1987-12-23 1995-07-01 Univ Leland Stanford Junior Mamiferos inmunodeficientes quimericos y su utilizacion.
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
DK0438053T3 (da) 1990-01-15 1999-11-22 Yeda Res & Dev Varig transplantation og udvikling af humane hæmopoietiske cellelinjer i normale pattedyr
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
AU637914B2 (en) 1990-05-03 1993-06-10 Systemix, Inc. Human lymphoid tissue in an immunocompromised host
JPH05500617A (ja) 1990-05-25 1993-02-12 システミックス，インコーポレイティド 免疫処理された宿主におけるヒト末梢血液細胞
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
EP0571525A1 (en) 1991-02-11 1993-12-01 OMMAYA, Ayub K. Spinal fluid driven artificial organ
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
EP0539970B1 (en) 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
US5663481A (en) 1993-08-06 1997-09-02 Mount Sinai Hospital Corporation Animal model of the human immune system
EP0771348A1 (en) 1994-07-27 1997-05-07 Merck & Co. Inc. Bradykinin b2 receptor modified transgenic non-human animals
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
JP4312265B2 (ja) 1997-04-09 2009-08-12 ラング−ジ チャン ワクチン評価のための動物モデル
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
JP2003508038A (ja) 1999-08-31 2003-03-04 ジェネンコア インターナショナル インコーポレーテッド ドナー特異的機能性免疫の産生を容易にすることができるトランスジェニック哺乳類
AU2066301A (en) 1999-12-09 2001-06-18 Human Genome Sciences, Inc. Il-6 like polynucleotide
WO2002022786A1 (en) 2000-09-14 2002-03-21 Genetrol Biotherapeutics, Inc. Method and cell composition for screening compounds for anti-inflammatory activity
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1414996T3 (da) * 2001-07-10 2011-03-21 Johnson & Johnson Res Pty Ltd Fremgangsmåder til genetisk modifikation af hæmatopoetiske progenitorceller og anvendelser af modificerede celler
WO2003039232A2 (en) 2001-10-26 2003-05-15 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
JP4087338B2 (ja) 2001-11-15 2008-05-21 キリンファーマ株式会社 キメラ非ヒト動物
WO2004005496A1 (ja) 2002-07-05 2004-01-15 Kirin Beer Kabushiki Kaisha 臍帯血、骨髄、末梢血等に含まれる新規な未分化幹細胞集団
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
AU2003278790A1 (en) 2002-09-09 2004-03-29 California Institute Of Technology Methods and compositions for the generation of humanized mice
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
WO2004060053A2 (en) 2002-12-16 2004-07-22 Genentech, Inc. Transgenic mice expressing human cd20
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
PT2019683T (pt) 2006-04-25 2017-03-17 Univ California Administração de fatores de crescimento para o tratamento de distúrbios do snc
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
WO2008069659A1 (en) 2006-12-05 2008-06-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
JP5666903B2 (ja) 2007-05-23 2015-02-12 サンガモ バイオサイエンシーズ， インコーポレイテッド 導入遺伝子の発現を増強するための方法および組成物
GB0718029D0 (en) 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
US20110118446A1 (en) 2007-09-28 2011-05-19 The General Hospital Corporation Methods and compositions for antibody production
CA2702217A1 (en) * 2007-10-11 2009-04-16 Jayne Danska Modulation of sirp.alpha. - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
US8521273B2 (en) 2008-01-29 2013-08-27 Gilbert H. KLIMAN Drug delivery devices, kits and methods therefor
WO2011002721A1 (en) * 2009-06-29 2011-01-06 Leskov Ilya B Non-human mammal model of human hematopoietic cancer
WO2011002727A1 (en) 2009-06-29 2011-01-06 Qingfeng Chen Methods of producing humanized non-human mammals
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
CA3040377C (en) 2009-10-06 2025-12-30 Yale University Genetically modified mice and engraftment comprising the knock-in of a human thrombopoietin (tpo) gene
WO2012040207A2 (en) * 2010-09-20 2012-03-29 Yale University HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
ES3040596T3 (en) 2011-02-15 2025-11-03 Regeneron Pharma Humanized m-csf mice and uses thereof
MY186903A (en) 2011-10-28 2021-08-26 Regeneron Pharma Humanized il-6 and il-6 receptor
KR102287541B1 (ko) 2012-09-07 2021-08-10 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
EP4389764B1 (en) 2012-11-05 2026-03-18 Regeneron Pharmaceuticals, Inc. Genetically modified rodents and methods of use thereof
DK3175706T3 (en) 2013-09-23 2019-03-04 Regeneron Pharma Non-human animals with a humanized signal regulatory protein gene
SMT201900177T1 (it) 2013-10-15 2019-05-10 Regeneron Pharma Animali con il-15 umanizzata
KR20250096864A (ko) 2014-05-19 2025-06-27 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
JP6752221B2 (ja) 2015-04-13 2020-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｓｉｒｐａ−ｉｌ１５ノックインマウス及びその使用方法

Also Published As

Publication number Publication date
JP2020168024A (ja) 2020-10-15
JP6283031B2 (ja) 2018-02-21
JP2015529083A (ja) 2015-10-05
JP7066785B2 (ja) 2022-05-13
JP7605789B2 (ja) 2024-12-24
US20150208622A1 (en) 2015-07-30
RU2015112607A (ru) 2016-10-27
IL307969A (en) 2023-12-01
JP6732998B2 (ja) 2020-07-29
CN108782459A (zh) 2018-11-13
KR102473555B1 (ko) 2022-12-05
KR20210044315A (ko) 2021-04-22
KR20150052274A (ko) 2015-05-13
EP4606818A2 (en) 2025-08-27
CN108782459B (zh) 2021-11-05
NZ704957A (en) 2018-05-25
EP4193834B1 (en) 2025-05-14
PT2892330T (pt) 2023-02-17
CN104955326A (zh) 2015-09-30
HK1211176A1 (en) 2016-05-20
NZ746089A (en) 2020-05-29
US20180020647A1 (en) 2018-01-25
RU2017145913A3 (enExample) 2021-08-16
JP2018088925A (ja) 2018-06-14
AU2013312359B2 (en) 2019-05-23
SG11201500504RA (en) 2015-02-27
MX364714B (es) 2019-05-06
US20190082663A1 (en) 2019-03-21
ES2938342T3 (es) 2023-04-10
US9820476B2 (en) 2017-11-21
US20210368752A1 (en) 2021-12-02
IL282472B2 (en) 2024-04-01
WO2014039782A3 (en) 2015-07-23
EP2892330B1 (en) 2022-11-23
CN113897398B (zh) 2025-07-08
KR20210099664A (ko) 2021-08-12
CA2881468A1 (en) 2014-03-13
DK2892330T3 (da) 2023-01-30
KR20220164808A (ko) 2022-12-13
IL282472B1 (en) 2023-12-01
IL307969B2 (en) 2026-02-01
AU2013312359B8 (en) 2019-08-15
JP2022105531A (ja) 2022-07-14
EP4193834C0 (en) 2025-05-14
MX2015002983A (es) 2015-06-17
US20200093105A1 (en) 2020-03-26
EP2892330A2 (en) 2015-07-15
MX2019005251A (es) 2019-08-05
IL282472A (en) 2021-06-30
MX385035B (es) 2025-03-14
NZ741951A (en) 2020-04-24
KR20230153500A (ko) 2023-11-06
KR102241962B1 (ko) 2021-04-20
WO2014039782A2 (en) 2014-03-13
JP6517958B2 (ja) 2019-05-22
IL236877A0 (en) 2015-03-31
IL265570A (en) 2019-05-30
CN104955326B (zh) 2018-07-20
JP2019110922A (ja) 2019-07-11
RU2768282C2 (ru) 2022-03-23
SG10201701759VA (en) 2017-04-27
AU2019216625B2 (en) 2021-07-08
KR20210156846A (ko) 2021-12-27
US10433527B2 (en) 2019-10-08
EP4606818A3 (en) 2025-10-22
KR102645622B1 (ko) 2024-03-11
EP4193834A1 (en) 2023-06-14
IL265570B (en) 2021-05-31
AU2021240324A1 (en) 2021-10-28
US12127537B2 (en) 2024-10-29
EP2892330A4 (en) 2016-07-27
CN113897398A (zh) 2022-01-07
KR102340059B1 (ko) 2021-12-17
ES3034290T3 (en) 2025-08-14
AU2013312359A1 (en) 2015-02-19
RU2017145913A (ru) 2019-02-19
RU2642319C2 (ru) 2018-01-24
IL307969B1 (en) 2025-10-01
IN2015DN02032A (enExample) 2015-08-14
KR102594390B1 (ko) 2023-10-27
KR20240045263A (ko) 2024-04-05
KR102287541B1 (ko) 2021-08-10
AU2019216625A1 (en) 2019-09-05
CA2881468C (en) 2023-03-21
CN120718856A (zh) 2025-09-30
AU2013312359A8 (en) 2019-08-15
US20250072405A1 (en) 2025-03-06
AU2021240324B2 (en) 2024-02-22
US11026408B2 (en) 2021-06-08

Similar Documents

Publication Publication Date Title
FI2892330T3 (fi) Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi
WO2016007570A3 (en) Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
MX2017009113A (es) Elementos regulatorios post-transcripcionales modificados de hepatitis.
RU2014148136A (ru) Композиции т-клеток с недостаточностью рецепторов т-клеток
HK1253945A1 (zh) 麥芽糖依賴性降解決定子、麥芽糖響應型啟動子、穩定化構建體及其在生成非分解代謝化合物中的用途
SG10201804330YA (en) Engineered high-affinity human t cell receptors
MX351916B (es) Polipeptidos que tienen actividad de lisozima y polinucleotdos que los codifican.
PH12014502418A1 (en) Enhanced affinity t cell receptors and methods for making the same
MY172726A (en) Humanized il-6 and il-6 receptor
WO2012100176A3 (en) Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation
WO2016135559A3 (en) Materials and methods for treatment of human genetic diseases including hemoglobinopathies
IN2014DN09960A (enExample)
MX337919B (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
MX2012006096A (es) Polipeptidos que tienen actividad glucoamilasa y polinucleotidos que codifican para los mismos.
NZ701791A (en) Cell culture compositions and methods for polypeptide production
WO2015100277A3 (en) Methods and compositions for ribosomal synthesis of macrocyclic peptides
WO2012116345A3 (en) Genetically engineered cyanobacteria
MX2015012171A (es) Promotores constitutivos de soja.
MX2014001594A (es) Polipeptidos que tienen actividad de celulasa y polinucleotidos que los codifican.
AR116615A2 (es) Operaciones de cosecha mejoradas para proteínas recombinadas
Eisenberg et al. T-cells “à la CAR-T (e)”–Genetically engineering T-cell response against cancer
MX369109B (es) Selección novedosa de vectores y métodos de selección de células hospederas eucarióticas.
MX349517B (es) Polipeptidos que tienen actividad de proteasa y polinucleotidos que codifican los mismos.
CO6450652A2 (es) Alteracion del equilibrio de enzimas mediante condiciones de fermentación
AR106255A1 (es) Plantas modificadas genéticamente para mejorar el rendimiento de cultivos